Gensignia Appoints CEO

Gensignia Ltd, a London-based privately held microRNA company, has appointed Lee McCracken as Chief Executive Officer of its wholly owned subsidiary, Gensignia Life Sciences, Inc.  He will lead the San Diego based operations to advance the company’s Dx/Rx business model in oncology, with an initial focus on launching the company’s molecular diagnostic test for early detection of lung cancer.

Mr McCracken has more than 20 years’ experience in the pharmaceutical, biotechnology, diagnostics and venture capital industries. He recently served as President and CEO of Pathwork Diagnostics.  Pathwork developed and commercialised an FDA-cleared molecular diagnostic for cancer, with Medicare and private payer reimbursement, and was sold to Response Genetics in 2013.

Previously, Mr McCracken held senior corporate roles at Prometheus Laboratories, Diversa, GenStar Therapeutics, CombiChem and Allergan. He began his career in venture capital at Union Venture before joining 3i Capital.

He holds a BS in Commerce / Marketing from Santa Clara University, a Master of Computer Science from University of Dayton and an MBA in Strategy / Venture Capital from the Anderson School of Management at UCLA.

“I am delighted to join Gensignia at an exciting time in its development and I look forward to working with the London, Milan, and San Diego teams in advancing our microRNA business to help patients around the world, initially by making a massive impact on lung cancer diagnosis and treatment," Mr McCracken said.